These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18665163)

  • 1. tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
    Wardley AM; Hiller L; Howard HC; Dunn JA; Bowman A; Coleman RE; Fernando IN; Ritchie DM; Earl HM; Poole CJ;
    Br J Cancer; 2008 Aug; 99(4):597-603. PubMed ID: 18665163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
    Earl HM; Hiller L; Howard HC; Dunn JA; Young J; Bowden SJ; McDermaid M; Waterhouse AK; Wilson G; Agrawal R; O'Reilly S; Bowman A; Ritchie DM; Goodman A; Hickish T; McAdam K; Cameron D; Dodwell D; Rea DW; Caldas C; Provenzano E; Abraham JE; Canney P; Crown JP; Kennedy MJ; Coleman R; Leonard RC; Carmichael JA; Wardley AM; Poole CJ;
    Lancet Oncol; 2017 Jun; 18(6):755-769. PubMed ID: 28479233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
    Earl HM; Vallier AL; Hiller L; Fenwick N; Young J; Iddawela M; Abraham J; Hughes-Davies L; Gounaris I; McAdam K; Houston S; Hickish T; Skene A; Chan S; Dean S; Ritchie D; Laing R; Harries M; Gallagher C; Wishart G; Dunn J; Provenzano E; Caldas C;
    Lancet Oncol; 2014 Feb; 15(2):201-12. PubMed ID: 24360787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
    Jones RL; Walsh G; Ashley S; Chua S; Agarwal R; O'Brien M; Johnston S; Smith IE
    Br J Cancer; 2009 Jan; 100(2):305-10. PubMed ID: 19165198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial.
    Poole C
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):23-6. PubMed ID: 15685822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
    Möbus V; Lück HJ; Ladda E; Klare P; Schmidt M; Schneeweiss A; Grischke EM; Wachsmann G; Forstbauer H; Untch M; Marmé F; Blohmer JU; Jackisch C; Huober J; Stickeler E; Reinisch M; Link T; Sinn BV; Janni W; Denkert C; Furlanetto J; Engels K; Solbach C; Schmatloch S; Rey J; Burchardi N; Loibl S;
    Eur J Cancer; 2021 Oct; 156():138-148. PubMed ID: 34450552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
    Piedbois P; Serin D; Priou F; Laplaige P; Greget S; Angellier E; Teissier E; Berdah JF; Fabbro M; Valenza B; Herait P; Jehl V; Buyse M
    Ann Oncol; 2007 Jan; 18(1):52-57. PubMed ID: 17047001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
    Hausmaninger H; Morack G; Heinrich B; Wallwiener D; Höffken K; Buksmaui S; Krejcy K; Miller MA; Possinger K
    Am J Clin Oncol; 2004 Aug; 27(4):429-35. PubMed ID: 15289740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study.
    Shao B; Song G; Li H; Dil L; Jiang H; Liang X; Yan Y; Zhang R; Ran R; Wang J; Liu X; You M
    J BUON; 2018; 23(6):1583-1590. PubMed ID: 30610781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
    Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
    Sánchez-Muñoz A; Dueñas-García R; Jaén-Morago A; Carrasco E; Chacón I; García-Tapiador AM; Ortega-Granados AL; Martínez-Ortega E; Ribelles N; Fernández-Navarro M; de la Torre-Cabrera C; Dueñas B; Rueda AI; Martínez J; Tortosa CR; Martín-Salvago MD; Sánchez-Rovira P
    Am J Clin Oncol; 2010 Oct; 33(5):432-7. PubMed ID: 19952716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
    Erman M; Baltali E; Karaoglu A; Abali H; Engin H; Ozisik Y; Guler N; Altundag K; Tekuzman G; Atahan IL; Onat D; Sayek I
    Cancer Invest; 2005; 23(3):215-21. PubMed ID: 15945507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
    von Minckwitz G; Möbus V; Schneeweiss A; Huober J; Thomssen C; Untch M; Jackisch C; Diel IJ; Elling D; Conrad B; Kreienberg R; Müller V; Lück HJ; Bauerfeind I; Clemens M; Schmidt M; Noeding S; Forstbauer H; Barinoff J; Belau A; Nekljudova V; Harbeck N; Loibl S
    J Clin Oncol; 2013 Oct; 31(28):3531-9. PubMed ID: 23980081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
    de Gregorio A; Häberle L; Fasching PA; Müller V; Schrader I; Lorenz R; Forstbauer H; Friedl TWP; Bauer E; de Gregorio N; Deniz M; Fink V; Bekes I; Andergassen U; Schneeweiss A; Tesch H; Mahner S; Brucker SY; Blohmer JU; Fehm TN; Heinrich G; Lato K; Beckmann MW; Rack B; Janni W
    Breast Cancer Res; 2020 Oct; 22(1):111. PubMed ID: 33097092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
    Sánchez-Muñoz A; Plata-Fernández Y; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Pascual J; Alba E; Sánchez-Rovira P
    Clin Transl Oncol; 2014 Jun; 16(6):548-54. PubMed ID: 24085576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
    Langley RE; Carmichael J; Jones AL; Cameron DA; Qian W; Uscinska B; Howell A; Parmar M
    J Clin Oncol; 2005 Nov; 23(33):8322-30. PubMed ID: 16293863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.